Tier 2 — strong

Unveiling the Anticancer Potential of Urolithin A in Colorectal Cancer: A Systematic Review

Francisco M, Mendes F, Martins D, Liberal J
Oncology Research 2026 34(2):3

Bibliography

PubMed
PMID 41646627
PubMed Central
PMC12868977
DOI
10.32604/or.2025.070276

Study snapshot

DesignPRISMA 2020 systematic review of in vitro colorectal-cancer studies
ModelHuman colorectal cancer cell models in included studies
SampleQualitative synthesis of eligible in vitro studies
InterventionUrolithin A alone or in experimental combinations
DurationVaried across included in vitro studies
EndpointsCell viability and proliferation; Apoptosis; Cell cycle; Migration/invasion; Molecular anticancer mechanisms

What the study showed, in plain terms

This 2026 systematic review maps Urolithin A's colorectal-cancer cell evidence. It supports a real preclinical anticancer research program but also makes the evidence boundary obvious: the included studies are in vitro, so the review cannot establish cancer prevention or treatment in humans.

Key findings

Multiple in vitro colorectal-cancer studies report antiproliferative or pro-apoptotic effects.

Several signaling mechanisms have been proposed across heterogeneous cell models.

The review provides a useful source map for a future cancer article.

What this study can and cannot tell us

The review intentionally included only in vitro evidence.

No human cancer efficacy or recurrence outcome can be inferred.

Concentrations and exposure times differ substantially across laboratory studies.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology